

Phospho-LATS1 (Ser909) Antibody



Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 140	Source/Isotype: Rabbit	UniProt ID: #O95835	Entrez-Gene Id: 9113
---------------------------	-------------------------	-----------------------------------	-------------------------	----------------------------------	-------------------------------	--------------------------------

Product Usage Information

Application

Western Blotting

Dilution

1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

Phospho-LATS1 (Ser909) Antibody detects endogenous levels of total LATS1 protein only when phosphorylated on Ser909. This antibody is predicted to cross react with LATS2 only when LATS2 is phosphorylated at Ser872.

Species predicted to react based on 100% sequence homology

Mouse, Rat, Monkey

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to amino acids surrounding Ser909 of human LATS1. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The Large tumor suppressor (LATS) proteins (LATS1, LATS2) are serine/threonine kinases that belong to the NDR family (1). The *Drosophila* homolog (warts) was first identified as a tumor suppressor protein that plays a role in the maintenance of ploidy. Human LATS1 was shown to localize to the centrosome and the mitotic spindle and control G2/M transition by negatively regulating cdc2 kinase activity (2,3). LATS1 is also reported to play a role in the G1 tetraploidy checkpoint, via control of p53 expression (4). LATS1 affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1 (5). LATS1 also binds the phosphorylated form of zyxin, a regulator of actin filament assembly. This interaction promotes localization of zyxin to the mitotic spindle, suggesting a role for actin regulatory proteins during mitosis (6). Decreased expression of LATS1 is associated with breast tumor aggressiveness (7), and mutations perturbing LATS1 have been associated with human sarcomas and ovarian sarcomas (8,9). LATS1 knockout mice develop soft-tissue sarcomas, ovarian stromal cell tumor, and display a high sensitivity to carcinogenic treatments (10). LATS1 and LATS2 have also been identified as key members of the Hippo signaling pathway, a conserved kinase cascade that functions to regulate cell growth and apoptosis (11). Phosphorylation of LATS by Mammalian Sterile-20-like proteins (e.g., MST1) results in LATS-mediated phosphorylation of the transcriptional co-activators YAP and TAZ (12, 13). LATS-mediated phosphorylation of YAP and TAZ promotes their cytoplasmic sequestration and association with 14-3-3 proteins, and subsequent proteasomal degradation, leading to downregulation of YAP/TAZ target genes that promote cell growth (11, 14).

Background References

1. Tao, W. et al. (1999) *Nat Genet* 21, 177-81.
2. Yang, X. et al. (2001) *Oncogene* 20, 6516-23.
3. Xia, H. et al. (2002) *Oncogene* 21, 1233-41.
4. Iida, S. et al. (2004) *Oncogene* 23, 5266-74.
5. Yang, X. et al. (2004) *Nat Cell Biol* 6, 609-17.
6. Hirota, T. et al. (2000) *J Cell Biol* 149, 1073-86.
7. Morinaga, N. et al. (2000) *Int J Oncol* 17, 1125-9.
8. Hansen, L.L. et al. (2002) *Cancer Genet Cytogenet* 139, 1-8.
9. Hisaoka, M. et al. (2002) *Lab Invest* 82, 1427-35.
10. St John, M.A. et al. (1999) *Nat Genet* 21, 182-6.
11. Guo, C. et al. (2007) *Curr Biol* 17, 700-5.
12. Hergovich, A. et al. (2006) *Biochem Biophys Res Commun* 345, 50-8.
13. Hirabayashi, S. et al. (2008) *Oncogene* 27, 4281-92.
14. Zhao, B. et al. (2010) *J Cell Sci* 123, 4001-6.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween@ 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.